Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 4—April 2008
Synopsis

Potential Use of Antiviral Agents in Polio Eradication

Armando M. De Palma*, Gerhard Pürstinger†, Eva Wimmer†, Amy K. Patick‡, Koen Andries§, Bart Rombaut¶, Erik De Clercq*, and Johan Neyts*Comments to Author 
Author affiliations: *University of Leuven, Leuven, Belgium; †University of Innsbruck, Innsbruck, Austria; ‡Pfizer Global Research and Development, San Diego, California, USA; §J&J Pharmaceutical Research and Development, Beerse, Belgium; ¶Vrije Universiteit Brussel, Brussels, Belgium;

Main Article

Figure 2

Effect of selected inhibitors on production of infectious poliovirus 1 Sabin in HeLa cell cultures. Supernatants collected from 3 independent experiments were titrated for infectious virus content, and 50% cell culture infective dose (CCID50) values were calculated as described by Reed and Muench (34). A) Ruprintrivir; B) enviroxime; C) MRL-1237; D) pleconaril.

Figure 2. Effect of selected inhibitors on production of infectious poliovirus 1 Sabin in HeLa cell cultures. Supernatants collected from 3 independent experiments were titrated for infectious virus content, and 50% cell culture infective dose (CCID50) values were calculated as described by Reed and Muench (34). A) Ruprintrivir; B) enviroxime; C) MRL-1237; D) pleconaril.

Main Article

References
  1. Griffiths  E, Wood  D, Barreto  L. Polio vaccine: the first 50 years and beyond. Biologicals. 2006;34:73–4. DOIPubMedGoogle Scholar
  2. Kimman  TG, Boot  H. The polio eradication effort has been a great success–let's finish it and replace it with something even better. Lancet Infect Dis. 2006;6:675–8. DOIPubMedGoogle Scholar
  3. Arita  I, Nakane  M, Fenner  F. Public health. Is polio eradication realistic? Science. 2006;312:852–4. DOIPubMedGoogle Scholar
  4. Minor  PD. Polio eradication, cessation of vaccination and re-emergence of disease. Nat Rev Microbiol. 2004;2:473–82. DOIPubMedGoogle Scholar
  5. Aylward  RB, Sutter  RW, Heymann  DL. Policy. OPV cessation—the final step to a “polio-free” world. Science. 2005;310:625–6. DOIPubMedGoogle Scholar
  6. Couzin  J. Report concludes polio drugs are needed–after disease is eradicated. Science. 2006;311:1539a. DOIPubMedGoogle Scholar
  7. MacLennan  C, Dunn  G, Huissoon  AP, Kumararatne  DS, Martin  J, O’Leary  P, Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet. 2004;363:1509–13. DOIPubMedGoogle Scholar
  8. De Palma  AM, Vliegen  I, De Clercq  E, Neyts  J. Selective inhibitors of picornavirus replication. Med Res Rev. 2008.
  9. Palma  AM, Heggermont  W, Leyssen  P, Purstinger  G, Wimmer  E, De Clercq  K, Anti-enterovirus activity and structure-activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[3,4-α]benzimidazoles. Biochem Biophys Res Commun. 2007;353:628–32. DOIPubMedGoogle Scholar
  10. McKinlay  MA, Pevear  DC, Rossmann  MG. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu Rev Microbiol. 1992;46:635–54.PubMedGoogle Scholar
  11. Florea  NR, Maglio  D, Nicolau  DP. Pleconaril, a novel antipicornaviral agent. Pharmacotherapy. 2003;23:339–48. DOIPubMedGoogle Scholar
  12. Hayden  FG, Hipskind  GJ, Woerner  DH, Eisen  GF, Janssens  M, Janssen  PA, Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother. 1995;39:290–4.PubMedGoogle Scholar
  13. Rotbart  HA, Webster  AD. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis. 2001;32:228–35. DOIPubMedGoogle Scholar
  14. Buttinelli  G, Donati  V, Fiore  S, Marturano  J, Plebani  A, Balestri  P, Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J Gen Virol. 2003;84:1215–21. DOIPubMedGoogle Scholar
  15. Andries  K, Rombaut  B, Dewindt  B, Boeye  A. Discrepancy between infectivity and antigenicity stabilization of oral poliovirus vaccine by a capsid-binding compound. J Virol. 1994;68:3397–400.PubMedGoogle Scholar
  16. Witherell  G. AG-7088 Pfizer. Curr Opin Investig Drugs. 2000;1:297–302.PubMedGoogle Scholar
  17. Patick  AK, Binford  SL, Brothers  MA, Jackson  RL, Ford  CE, Diem  MD, In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 1999;43:2444–50.PubMedGoogle Scholar
  18. Patick  AK. Rhinovirus chemotherapy. Antiviral Res. 2006;71:391–6. DOIPubMedGoogle Scholar
  19. DeLong  DC, Reed  SE. Inhibition of rhinovirus replication in organ culture by a potential antiviral drug. J Infect Dis. 1980;141:87–91.PubMedGoogle Scholar
  20. Heinz  BA, Vance  LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol. 1995;69:4189–97.PubMedGoogle Scholar
  21. Wyde  PR, Six  HR, Wilson  SZ, Gilbert  BE, Knight  V. Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother. 1988;32:890–5.PubMedGoogle Scholar
  22. Higgins  PG, Barrow  GI, al Nakib  W, Tyrrell  DA, DeLong  DC, Lenox-Smith  I. Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers. Antiviral Res. 1988;10:141–9. DOIPubMedGoogle Scholar
  23. Miller  FD, Monto  AS, DeLong  DC, Exelby  A, Bryan  ER, Srivastava  S. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob Agents Chemother. 1985;27:102–6.PubMedGoogle Scholar
  24. Phillpotts  RJ, Jones  RW, DeLong  DC, Reed  SE, Wallace  J, Tyrrell  DA. The activity of enviroxime against rhinovirus infection in man. Lancet. 1981;317:1342–4. DOIPubMedGoogle Scholar
  25. Victor  F, Loncharich  R, Tang  J, Spitzer  WA. Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality. J Med Chem. 1997;40:3478–83. DOIPubMedGoogle Scholar
  26. Victor  F, Brown  TJ, Campanale  K, Heinz  BA, Shipley  LA, Su  KS, Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime. J Med Chem. 1997;40:1511–8. DOIPubMedGoogle Scholar
  27. Manns  MP, Wedemeyer  H, Cornberg  M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350–9. DOIPubMedGoogle Scholar
  28. Sidwell  RW, Barnard  DL. Respiratory syncytial virus infections: recent prospects for control. Antiviral Res. 2006;71:379–90. DOIPubMedGoogle Scholar
  29. Carroll  SS, Tomassini  JE, Bosserman  M, Getty  K, Stahlhut  MW, Eldrup  AB, Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J Biol Chem. 2003;278:11979–84. DOIPubMedGoogle Scholar
  30. Goris  N, De Palma  A, Toussaint  JF, Musch  I, Neyts  J, De Clercq  K. 2′-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res. 2007;73:161–8. DOIPubMedGoogle Scholar
  31. Hadaschik  D, Klein  M, Zimmermann  H, Eggers  HJ, Nelsen-Salz  B. Dependence of echovirus 9 on the enterovirus RNA replication inhibitor 2-(alpha-hydroxybenzyl)-benzimidazole maps to nonstructural protein 2C. J Virol. 1999;73:10536–9.PubMedGoogle Scholar
  32. Shimizu  H, Agoh  M, Agoh  Y, Yoshida  H, Yoshii  K, Yoneyama  T, Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J Virol. 2000;74:4146–54. DOIPubMedGoogle Scholar
  33. Powers  RD, Gwaltney  JM Jr, Hayden  FG. Activity of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) against picornaviruses in vitro. Antimicrob Agents Chemother. 1982;22:639–42.PubMedGoogle Scholar
  34. Reed  SE, Meunch  H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493–7.
  35. Patick  AK, Brothers  MA, Maldonado  F, Binford  S, Maldonado  O, Fuhrman  S, In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 2005;49:2267–75. DOIPubMedGoogle Scholar
  36. Barnard  DL, Hubbard  VD, Smee  DF, Sidwell  RW, Watson  KG, Tucker  SP, In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother. 2004;48:1766–72. DOIPubMedGoogle Scholar
  37. Smith  DB, Martin  JA, Klumpp  K, Baker  SJ, Blomgren  PA, Devos  R, Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. Bioorg Med Chem Lett. 2007;17:2570–6. DOIPubMedGoogle Scholar
  38. Vignuzzi  M, Stone  JK, Andino  R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 2005;107:173–81. DOIPubMedGoogle Scholar
  39. World Health Organization. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva, 11–12 October 2006, Part II. Wkly Epidemiol Rec. 2006;81:465–8.PubMedGoogle Scholar

Main Article

Page created: July 16, 2010
Page updated: July 16, 2010
Page reviewed: July 16, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external